Cystic Fibrosis Carrier States Are Associated With More Severe Cases of Bronchiectasis

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2024 Feb 23

PMID 38390464

Authors

Aaron C Miller

Logan M Harris

Kevin L Winthrop

Joseph E Cavanaugh

Mahmoud H Abou Alaiwa

Douglas B Hornick

David A Stoltz

Philip M Polgreen

Affiliations

Soon will be listed here.

Abstract

Background: People with cystic fibrosis (CF) are at increased risk for bronchiectasis, and several reports suggest that CF carriers may also be at higher risk for developing bronchiectasis. The purpose of this study was to determine if CF carriers are at risk for more severe courses or complications of bronchiectasis.

Methods: Using MarketScan data (2001-2021), we built a cohort consisting of 105 CF carriers with bronchiectasis and 300 083 controls with bronchiectasis but without a CF carrier diagnosis. We evaluated if CF carriers were more likely to be hospitalized for bronchiectasis. In addition, we examined if CF carriers were more likely to be infected with or nontuberculous mycobacteria (NTM) or to have filled more antibiotic prescriptions. We considered regression models for incident and rate outcomes that controlled for age, sex, smoking status, and comorbidities.

Results: The odds of hospitalization were almost 2.4 times higher (95% CI, 1.116-5.255) for CF carriers with bronchiectasis when compared with non-CF carriers with bronchiectasis. The estimated odds of being diagnosed with a infection for CF carriers vs noncarriers was about 4.2 times higher (95% CI, 2.417-7.551) and 5.4 times higher (95% CI, 3.398-8.804) for being diagnosed with NTM. The rate of distinct antibiotic fill dates was estimated to be 2 times higher for carriers as compared with controls (95% CI, 1.735-2.333), and the rate ratio for the total number of days of antibiotics supplied was estimated as 2.8 (95% CI, 2.290-3.442).

Conclusions: CF carriers with bronchiectasis required more hospitalizations and more frequent administration of antibiotics as compared with noncarriers. Given that CF carriers were also more likely to be diagnosed with and NTM infections, CF carriers with bronchiectasis may have a phenotype more resembling CF-related bronchiectasis than non-CF bronchiectasis.

References

Daviskas E, Anderson S, Eberl S, Chan H, BAUTOVICH G . Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med. 1999; 159(6):1843-8. DOI: 10.1164/ajrccm.159.6.9809074. View

Weycker D, Hansen G, Seifer F . Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. Chron Respir Dis. 2017; 14(4):377-384. PMC: 5729734. DOI: 10.1177/1479972317709649. View

Tzetis M, Efthymiadou A, Strofalis S, Psychou P, Dimakou A, Pouliou E . CFTR gene mutations--including three novel nucleotide substitutions--and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease. Hum Genet. 2001; 108(3):216-21. DOI: 10.1007/s004390100467. View

Hamzeh H, Spencer S, Kelly C . Development of a core outcome set and outcome measurement set for physiotherapy trials in adults with Bronchiectasis (COS-PHyBE study): A protocol. PLoS One. 2022; 17(2):e0263695. PMC: 8824374. DOI: 10.1371/journal.pone.0263695. View

Girodon E, Cazeneuve C, Lebargy F, Chinet T, Costes B, Ghanem N . CFTR gene mutations in adults with disseminated bronchiectasis. Eur J Hum Genet. 1997; 5(3):149-55. View

Wang G, Nauseef W . Neutrophil dysfunction in the pathogenesis of cystic fibrosis. Blood. 2022; 139(17):2622-2631. PMC: 9053701. DOI: 10.1182/blood.2021014699. View

Bienvenu T, Sermet-Gaudelus I, Burgel P, Hubert D, Crestani B, Bassinet L . Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2010; 181(10):1078-84. DOI: 10.1164/rccm.200909-1434OC. View

Tarrant B, Le Maitre C, Romero L, Steward R, Button B, Thompson B . Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis. Respirology. 2017; 22(6):1084-1092. DOI: 10.1111/resp.13047. View

Castellani C, Assael B . Cystic fibrosis: a clinical view. Cell Mol Life Sci. 2016; 74(1):129-140. PMC: 11107741. DOI: 10.1007/s00018-016-2393-9. View

10.

Kapur N, Stroil-Salama E, Morgan L, Yerkovich S, Holmes-Liew C, King P . Factors associated with "Frequent Exacerbator" phenotype in children with bronchiectasis: The first report on children from the Australian Bronchiectasis Registry. Respir Med. 2021; 188:106627. DOI: 10.1016/j.rmed.2021.106627. View

11.

Chalmers J, Aliberti S, Filonenko A, Shteinberg M, Goeminne P, Hill A . Characterization of the "Frequent Exacerbator Phenotype" in Bronchiectasis. Am J Respir Crit Care Med. 2018; 197(11):1410-1420. DOI: 10.1164/rccm.201711-2202OC. View

12.

Araujo D, Shteinberg M, Aliberti S, Goeminne P, Hill A, Fardon T . The independent contribution of infection to long-term clinical outcomes in bronchiectasis. Eur Respir J. 2018; 51(2). DOI: 10.1183/13993003.01953-2017. View

13.

Aliberti S, Lonni S, Dore S, McDonnell M, Goeminne P, Dimakou K . Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J. 2016; 47(4):1113-22. DOI: 10.1183/13993003.01899-2015. View

14.

Mehr S . The immunological investigation of a child with chronic wet cough. Paediatr Respir Rev. 2012; 13(3):144-9. DOI: 10.1016/j.prrv.2012.02.001. View

15.

Robinson M, Bye P . Mucociliary clearance in cystic fibrosis. Pediatr Pulmonol. 2002; 33(4):293-306. DOI: 10.1002/ppul.10079. View

16.

Chalmers J, Chang A, Chotirmall S, Dhar R, McShane P . Bronchiectasis. Nat Rev Dis Primers. 2018; 4(1):45. DOI: 10.1038/s41572-018-0042-3. View

17.

Miller A, Comellas A, Hornick D, Stoltz D, Cavanaugh J, Gerke A . Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions. Proc Natl Acad Sci U S A. 2019; 117(3):1621-1627. PMC: 6983448. DOI: 10.1073/pnas.1914912117. View

18.

Bobadilla J, Macek Jr M, Fine J, Farrell P . Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. Hum Mutat. 2002; 19(6):575-606. DOI: 10.1002/humu.10041. View

19.

Quint J, Millett E, Joshi M, Navaratnam V, Thomas S, Hurst J . Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J. 2015; 47(1):186-93. PMC: 4982534. DOI: 10.1183/13993003.01033-2015. View

20.

Elborn J . Cystic fibrosis. Lancet. 2016; 388(10059):2519-2531. DOI: 10.1016/S0140-6736(16)00576-6. View